Shares of Roquefort Therapeutics plc (LON:ROQ – Get Free Report) fell 6.9% during trading on Friday . The stock traded as low as GBX 3.55 ($0.04) and last traded at GBX 3.68 ($0.05). 1,670,536 shares changed hands during mid-day trading, an increase of 25% from the average session volume of 1,334,411 shares. The stock had previously closed at GBX 3.95 ($0.05).
Roquefort Therapeutics Trading Down 10.8 %
The firm’s fifty day simple moving average is GBX 4.06 and its 200-day simple moving average is GBX 4.06. The company has a debt-to-equity ratio of 12.37, a quick ratio of 3.07 and a current ratio of 0.79. The stock has a market cap of £4.55 million, a P/E ratio of -352.50 and a beta of 0.05.
About Roquefort Therapeutics
Roquefort Therapeutics is a LSE Main Market listed biotech company developing first in class drugs in the high value and high growth oncology segment prior to partnering or selling to big pharma. Since listing in March 2021, Roquefort Therapeutics has successfully acquired Lyramid Pty Limited, a leader in the development of medicines for a new therapeutic target, Midkine (a human growth factor associated with cancer progression), and most recently acquired Oncogeni Ltd, founded by Nobel Laureate Professor Sir Martin Evans, which has developed two families of innovative cell and RNA oncology medicines.
Further Reading
- Five stocks we like better than Roquefort Therapeutics
- What Are the FAANG Stocks and Are They Good Investments?
- Why Energy Transfer Stock Could Soar to New Highs in 2025
- Asset Allocation: The Key to a Successful Portfolio. Are You Paying Attention to Yours?
- 3 Buy-and-Hold Stocks for Long-Term Growth
- Short Selling: How to Short a Stock
- Despite Short-Term Risks Freeport McMoran Worth a Look
Receive News & Ratings for Roquefort Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Roquefort Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
